Elisabeth Kogan
CEO & Co-founder
Claimed by owner Clexio Biosciences
Former names:
Drug Therapies for Treatment of Neurological Conditions
Clexio Biosciences
About
Clexio Biosciences is a clinical-stage pharmaceutical company developing CNS therapies designed to address patients unmet needs through a scientifically based fusion of drugs and innovative technologies.
Clexios growing pipeline is focused on the development of safe and effective treatments with rapid onset of action for a wide range of neurological and psychiatric conditions, including major depressive disorder, Parkinsons disease, pain, and other conditions involving impairment of the neurological system.
Clexios growing pipeline is focused on the development of safe and effective treatments with rapid onset of action for a wide range of neurological and psychiatric conditions, including major depressive disorder, Parkinsons disease, pain, and other conditions involving impairment of the neurological system.
Employees
Product stage
Primary Sector
Life Sciences & HealthTech
Products
CLE-400, CLE-500, CLE-300, CLE-600, CLE-100
Geographic markets
Global
Funding
Total Funding
Undisclosed
Last Funding
Undisclosed
Funding Stage
Total Rounds
0
Investors
0
News
(0)The Team
(7)
EK
EK
Elisabeth Kogan
CEO & Co-founder
ML
Menashe Levy
Co-founder & CTO
EH
Esther Hagai
CMO
OE
Orly Eini
Head of HR
Hila Mark
Administrative Manager
David Dangoor PhD, MBA
Business Analyst
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Media gallery
(2)
Locations
Israel
Yegi'a Kapayim St 17, Petah Tikva, Israel
Jerusalem, Israel
Locations
Israel
Yegi'a Kapayim St 17, Petah Tikva, Israel
Jerusalem, Israel
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,